Table 3.
Medical and Aflatoxin B1 Exposure Characteristics of Study Participants, Eastern Ethiopia, 2020/21
| Characteristics | Cases 127 (%) | Controls 253 (%) |
|---|---|---|
| Family history of liver disease* | ||
| No | 111 (87) | 245 (97) |
| Yes | 16 (13) | 8 (3) |
| Herbal medicine use | ||
| No | 115 (91) | 233 (92) |
| Yes | 12 (9) | 20 (8) |
| HBV positive* | ||
| No | 100 (79) | 239 (94.5) |
| Yes | 27 (21) | 14 (5.5) |
| HCV positive | ||
| No | 126 (99.2) | 252 (99.6) |
| Yes | 1(0.8) | 1 (0.4) |
| Detectable AF-alb adduct* | ||
| No | 32 (25) | 91 (36) |
| Yes | 95 (75) | 162 (64) |
| AF-alb adduct levels, median (IQR)a,* | 11 (5.5–25) | 7.0 (4.3–20.5) |
| Lowb | 38 (30) | 91 (36) |
| Highb | 57 (45) | 71 (28)* |
Notes: N= 380; n for cases=127; n for controls =253; *p value < 0.05 (from chi-square or Fisher exact test). aAF-alb adduct concentration (pg/mg albumin); bLow and high were < 8.6 and > 8.6 pg/mg albumin respectively.
Abbreviations: AF-alb adduct, aflatoxin B1 (AFB1) albumin adduct; HBV, Hepatitis B Virus; HCV, Hepatitis C Virus; IQR, inter quartile range.